Literature DB >> 15647999

Inflammation and carnitine in hemodialysis patients.

Giovanni Pertosa1, Giuseppe Grandaliano, Simona Simone, Michela Soccio, Francesco Paolo Schena.   

Abstract

The bioincompatibility of dialytic systems along with the loss of antioxidant substances via the dialysis may contribute to peripheral blood mononuclear cell (PBMC) activation and the production of inflammatory mediators, such as cytokines, oxygen radicals, and complement fragments, that may sustain a state of chronic microinflammation responsible for the pathogenesis of a variety of diseases, including atherosclerosis, anemia, and malnutrition. Moreover, during hemodialysis (HD), oxidative stress may influence several intracellular signaling enzymes, including some stress-activated kinases, such as jun-N-terminal kinase (JNK), potentially leading to PBMC activation and proinflammatory cytokine production. Recent reports suggest that L-carnitine may play an important role in balancing antioxidative systems. Therefore, we sought to evaluate the effect of L-carnitine supplementation on the PBMC responses to oxidative stress induced by different HD membranes. We observed in PBMC from cellulosic (C)-treated patients an increase in the amount of intracellular tyrosine-phosphorylated proteins and a striking activation of JNK, as compared with synthetic (S)-treated patients. On the contrary, 3 months of L-carnitine supplementation significantly lowered intracellular levels of phosphorylated proteins and JNK activity in PBMC from C-treated patients. In addition, after 180 minutes of HD, a significant decrease in global plasma antioxidant capacity was found, particularly in C-treated patients, whereas L-carnitine supplementation improved plasma antioxidant capacity levels in these patients. These observations were also confirmed by in vitro experiments, showing the ability of L-carnitine to reduce the JNK activation in normal PBMC exposed to different amounts of hydrogen peroxide. In conclusion, the uremic milieu is characterized by an enhanced inflammatory response and an increased oxidant load, affecting lipids, carbohydrates, and proteins. Regular L-carnitine supplementation in HD patients can improve cellular defense against chronic inflammation and oxidative stress, most likely by modulating the specific signal transduction cascade activated by an overproduction of proinflammatory cytokines and oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647999     DOI: 10.1053/j.jrn.2004.09.031

Source DB:  PubMed          Journal:  J Ren Nutr        ISSN: 1051-2276            Impact factor:   3.655


  8 in total

1.  Investigation of inflammatory profile in MSUD patients: benefit of L-carnitine supplementation.

Authors:  Caroline Paula Mescka; Gilian Guerreiro; Bruna Donida; Desirèe Marchetti; Carlos Alberto Yasin Wayhs; Graziela Schimitt Ribas; Adriana Simon Coitinho; Moacir Wajner; Carlos Severo Dutra-Filho; Carmen Regla Vargas
Journal:  Metab Brain Dis       Date:  2015-05-24       Impact factor: 3.584

2.  Beneficial effects of combination therapy of intradialytic parenteral nutrition and oral L-carnitine administration.

Authors:  Masataka Tsunoda; Ryota Ikee; Naomi Sasaki; Nobuo Hashimoto
Journal:  Int Urol Nephrol       Date:  2012-09-11       Impact factor: 2.370

Review 3.  Inflammation and L-carnitine therapy in hemodialysis patients: a review.

Authors:  Saman Khalatbari-Soltani; Hadi Tabibi
Journal:  Clin Exp Nephrol       Date:  2014-12-02       Impact factor: 2.801

4.  Effects of levocarnitine on brachial-ankle pulse wave velocity in hemodialysis patients: a randomized controlled trial.

Authors:  Terumi Higuchi; Masanori Abe; Toshio Yamazaki; Mari Mizuno; Erina Okawa; Hideyuki Ando; Osamu Oikawa; Kazuyoshi Okada; Fumito Kikuchi; Masayoshi Soma
Journal:  Nutrients       Date:  2014-12-22       Impact factor: 5.717

5.  Efficacy of L-carnitine supplementation on frailty status and its biomarkers, nutritional status, and physical and cognitive function among prefrail older adults: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  M Badrasawi; Suzana Shahar; A M Zahara; R Nor Fadilah; Devinder Kaur Ajit Singh
Journal:  Clin Interv Aging       Date:  2016-11-17       Impact factor: 4.458

Review 6.  Naturally Occurring Compounds: New Potential Weapons against Oxidative Stress in Chronic Kidney Disease.

Authors:  Lorenzo Signorini; Simona Granata; Antonio Lupo; Gianluigi Zaza
Journal:  Int J Mol Sci       Date:  2017-07-10       Impact factor: 5.923

7.  Association of Low Serum l-Carnitine Levels with Peripheral Arterial Stiffness in Patients Who Undergo Kidney Transplantation.

Authors:  Yu-Hsien Lai; Ming-Che Lee; Guan-Jin Ho; Chin-Hung Liu; Bang-Gee Hsu
Journal:  Nutrients       Date:  2019-08-24       Impact factor: 5.717

Review 8.  Mitochondria: a new therapeutic target in chronic kidney disease.

Authors:  Simona Granata; Alessandra Dalla Gassa; Paola Tomei; Antonio Lupo; Gianluigi Zaza
Journal:  Nutr Metab (Lond)       Date:  2015-11-25       Impact factor: 4.169

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.